Valuation: Unicycive Therapeutics, Inc.

Market Cap 15Cr 13Cr 12Cr 11Cr 22Cr 1.46TCr 22Cr 147.56Cr 57Cr 716.04Cr 57Cr 56Cr 2.47TCr P/E 2026 *
-4.05x
P/E 2027 * 1.11x
Enterprise Value 15Cr 13Cr 12Cr 11Cr 22Cr 1.46TCr 22Cr 147.56Cr 57Cr 716.04Cr 57Cr 56Cr 2.47TCr EV / Sales 2026 *
36.2x
EV / Sales 2027 * 0.51x
Free-Float
97.64%
Yield 2026 *
72.8%
Yield 2027 * 40.7%
1 day+8.52%
1 week-19.64%
Current month+22.17%
1 month-20.42%
3 months-17.32%
6 months-1.21%
Current year-0.69%
1 week 3.93
Extreme 3.93
8.05
1 month 3.93
Extreme 3.93
8.56
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
87.3
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap.
14/05Free

Director

1,26,300 0.5004%
14/05Free

Chief Operating Officer

1,69,500 0.6716%
14/05Free

Chief Financial Officer

1,69,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
+8.52%-19.64%+24.57%-50.17% 15Cr
+0.68%+5.92%+80.45%+137.78% 5.91TCr
+2.32%+5.03%+75.51%+94.88% 5.52TCr
+3.86%+6.93%-11.32%-9.53% 2.47TCr
+4.30%+7.95%+14.11%+437.83% 2.42TCr
+4.74%+13.68%+45.58%-1.42% 1.97TCr
-0.29%+9.78%+44.62%-27.94% 1.76TCr
0.00%+20.78%+178.93%+360.74% 1.62TCr
+3.50%+1.97%+21.02%+191.95% 1.4TCr
+6.72%+19.38%+42.82% - 1.48TCr
Average +3.44%+4.69%+51.63%+126.01% 2.46TCr
Weighted average by Cap. +2.47%+6.45%+59.03%+137.58%

Financials

2026 *2027 *
Net sales 42.27L 36.95L 33.96L 31.65L 60.04L 40Cr 60.95L 4.08Cr 1.58Cr 20Cr 1.59Cr 1.55Cr 68Cr 30Cr 26Cr 24Cr 22Cr 43Cr 2.86TCr 43Cr 289.62Cr 112.59Cr 1.41TCr 112.71Cr 110.29Cr 4.84TCr
Net income -4.03Cr -3.53Cr -3.24Cr -3.02Cr -5.73Cr -384.07Cr -5.82Cr -39Cr -15Cr -188.79Cr -15Cr -15Cr -650.55Cr 19Cr 16Cr 15Cr 14Cr 26Cr 1.77TCr 27Cr 179.59Cr 70Cr 871.46Cr 70Cr 68Cr 3TCr
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
02/26/02 $5.730 +8.52% 29,93,015
01/26/01 $5.280 +12.58% 60,57,842
30/26/30 $4.690 -39.09% 2,01,26,082
29/26/29 $7.700 +7.99% 25,93,482
26/26/26 $7.130 -13.15% 74,20,398
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.730USD
Average target price
39.54USD
Spread / Average Target
+590.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock